0.93% 0.0091

Ocean Biomedical Inc (OCEA)

Ocean Biomedical Inc 주식(OCEA)의 최신 뉴스

Ocean Biomedical Inc (OCEA)

Ocean Biomedical Inc 주식(OCEA)의 최신 뉴스

Dr. Chirinjeev Kathuria - Smart Business Dealmakers

Everything you need to know about Zenas BioPharma’s IPO - AlphaStreet

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Issued for PfGARP Malaria Antibodies Central to Company’s Malaria Treatment and Prevention Platforms - ForexTV.com

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent - GlobeNewswire

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Issued for PfGARP Malaria Antibodies Central to Company’s Malaria Treatment and Prevention Platforms - Morningstar

Ocean Biomedical, Inc. Announces Receipt of Notice from - GlobeNewswire

Ocean Biomedical Faces Nasdaq Compliance Challenges - TipRanks

Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q - StockTitan

Ocean Biomedical (NASDAQ: OCEA) Research Summary - AlphaStreet

Ocean Biomedical Inc. (OCEA) Stock: Navigating a Year of Volatility - The InvestChronicle

U.S. shares mixed at close of trade; Dow Jones Industrial Average up 0.16% - MSN

Ocean Biomedical secures additional financing, issues equity - Investing.com

Financial Health Check: Examining Ocean Biomedical Inc. (OCEA)'s Key Ratios – DWinneX - The Dwinnex

Ocean Biomedical Inc. (OCEA) is a good investment, but the stock may be overvalued – US Post News - US Post News

Everything you need to know about OS Therapies’ upcoming IPO - AlphaStreet

3-Month SOFR (SQZ24) Quote - The Globe and Mail

Alumis looks to raise $300 million in IPO. Here’s what you need to know - AlphaStreet

Idiopathic Pulmonary Fibrosis Pipeline Analysis 2024: FDA Approval, Clinical Trials, Therapies, MOA, ROA by - EIN News

The Role of Horseshoe Crabs in the Biomedical Industry and Recent Trends Impacting Species Sustainability - Frontiers

Investing in Ocean Biomedical Inc. (OCEA) might be an excellent idea, but the stock is currently overvalued ... - US Post News

Best Penny Stocks for Today (Charts Updated Daily) • Benzinga - Benzinga

Biotech Stock Roundup: ZGNX's Acquisition News, REGN, BLUE's Updates & More - Yahoo Lifestyle UK

Biotech Stocks: The Top 5 To Watch As Shares Broadly Struggle - Investor's Business Daily

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday - InvestorPlace

TSX 60 Index (TXSX) QuotePress Release - The Globe and Mail

Stocks Fall Before CPI Report and FOMC Meeting - The Globe and Mail

Stocks Settle Higher Ahead of the Tue/Wed FOMC Meeting - The Globe and Mail

Ocean Biomedical congratulates joint venture partner Virion TherapeuticsTipRanks.com - TipRanks

Tempus AI gears up for IPO. Here’s everything you need to know - AlphaStreet

Ocean Biomedical (NASDAQ: OCEA) Congratulates Joint Venture Partner, Virion Therapeutics, on Positive ... - GlobeNewswire

Ocean Biomedical (NASDAQ: OCEA) Congratulates Joint Venture Partner, Virion Therapeutics, on Positive Immunogenicity Results from Their Lead Checkpoint Modifier-Containing Immunotherapy, VRON-0200, for HBV Functional Cure, at EASL 2024 - ForexTV.com

Ocean Biomedical (NASDAQ: OCEA) Congratulates Joint Venture Partner, Virion Therapeutics, on Positive Immunogenicity Results from Their Lead Checkpoint Modifier-Containing Immunotherapy, VRON-0200, for HBV Functional Cure, at EASL 2024 - GlobeNewswire Inc.

Virion Therapeutics Reports Positive First-in-human, First-in-class, Phase 1b Immunogenicity Data of VRON-0200, a Novel Checkpoint Modifier for HBV Functional Cure at EASL Congress - PR Newswire

Virion Therapeutics Reports Positive First-in-human, First-in-class, Phase 1b Immunogenicity Data of VRON-0200, a ... - PR Newswire

Stocks Climb on Positive Corporate News - The Globe and Mail

Ocean Biomedical receives notice of non-compliance from NasdaqTipRanks.com - TipRanks

Ocean Biomedical Faces Nasdaq Non-Compliance Notice and DelaysTipRanks.com - TipRanks

Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form ... - GlobeNewswire

Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q - GlobeNewswire Inc.

Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q - Yahoo Finance

Stocks Mixed in TodayAfternoon Trade - Nasdaq

Ratio Review: Analyzing Ocean Biomedical Inc. (OCEA)'s Price-to-Cash and Price-to-Free Cash Flow – DWinneX - The Dwinnex

OCEA Stock Earnings: Ocean Biomedical Reported Results for Q3 2023 - InvestorPlace

Ocean Biomedical Inc.’s Shares Reel: 189.95% Quarterly Revenue Decline Amid 60.29M Market Cap - The InvestChronicle

Market Insight: Ocean Biomedical Inc. (OCEA)'s Notable Gain, Closing at 1.74 – DWinneX - The Dwinnex

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Allowance for Malaria Antibodies That Have Potential ... - Markets Insider

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Allowance for Malaria Antibodies That Have Potential ... - BioSpace

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Allowance for Malaria Antibodies That Have Potential Capability to Protect Against Infection and Treat Severe Disease - ForexTV.com

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Allowance for Malaria Antibodies That Have Potential - Daily Guardian Canada

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Allowance for Malaria Antibodies That Have Potential ... - GlobeNewswire

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Allowance for Malaria Antibodies That Have Potential ... - Nasdaq

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Allowance for Malaria Antibodies That Have Potential Capability to Protect Against Infection and Treat Severe Disease - BioSpace

Ocean Biomedical Inc. (OCEA) Stock: Uncovering 52-Week Market Trends – Invest Chronicle - The InvestChronicle

Why Is Helius Medical Technology (HSDT) Stock Up 47% Today? - InvestorPlace

RI biotech that's overdue on annual report told it's out of compliance by Nasdaq - The Business Journals

Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K - GlobeNewswire Inc.

Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K - Yahoo Finance

Why Is Palisade Bio (PALI) Stock Up 57% Today? - InvestorPlace

PACS Group gears up for $400 million IPO. Here’s all you need to know - AlphaStreet

Femasys is committed to providing women with revolutionary healthcare products: CEO - AlphaStreet

Russell 2000 index best and worst performing stocks of 2024 - Invezz

Largest borrow rate increases among liquid names - TipRanks

Ocean Biomedical (NASDAQ: OCEA) Congratulates JV Partner, Virion Therapeutics, on Promising First-Ever Human Phase 1B Clinical Safety Data for Their Lead Checkpoint Modifier-Containing Immunotherapy for HBV Functional Cure, at Global APASL - GlobeNewswire Inc.

Ocean Biomedical (NASDAQ: OCEA) Congratulates JV Partner, Virion Therapeutics, on Promising First-Ever Human Phase 1B Clinical Safety Data for Their Lead Checkpoint Modifier-Containing Immunotherapy for HBV Functional Cure, at Global APASL - GlobeNewswire

OCEA과 유사한 종목